Chunzhi Xia
Medical Oncology · Cumming, GANPI 1639348766
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,915 of the $23,614 with a category attached, or 71.6%. 37 manufacturers reported payments, led by Daiichi Sankyo Inc. at 32.6% of the total. Reporting peaked in 2024 at $19,500 and has fallen 84.4% since, to $3,034 in 2025.
Across 131 payments — averaging $180.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$8K
- AstraZeneca$6K
- Gilead$4K
- Pharmacosmos Therapeutics Inc.$3K
- Jazz Pharmaceuticals Inc.$1K
- Beigene USA, Inc.$675
- plus $2K from 31 others
What the payments were for
- Consulting fees$16,91572%
- Speaking & faculty fees$2,0509%
- Grants$3501%
- Travel & lodging$1,7647%
- Food & beverage$2,40510%
- Education$1301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 14 | $7,703 |
| AstraZeneca(2 entities) | 26 | $5,512 |
| Gilead | 12 | $3,950 |
| Pharmacosmos Therapeutics Inc. | 10 | $2,647 |
| Jazz Pharmaceuticals Inc. | 2 | $1,454 |
| Beigene USA, Inc. | 1 | $675 |
| Pfizer | 15 | $226 |
| Sobi, Inc | 2 | $222 |
| Astellas Pharma US Inc | 2 | $130 |
| Novartis | 5 | $100 |
| Stemline Therapeutics Inc. | 1 | $98 |
| Incyte Corporation | 4 | $74 |
| Array Biopharma Inc | 6 | $71 |
| Puma Biotechnology, Inc. | 3 | $66 |
| Bristol Myers Squibb | 3 | $64 |
| Genentech USA, Inc. | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| EMD Serono, Inc. | 1 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Taiho Oncology, Inc. | 1 | $35 |
| Tersera Therapeutics LLC | 1 | $34 |
| Sanofi | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Caris MPI, Inc. | 1 | $29 |
| Merck | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| AbbVie | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Bayer | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Pharmaessentia USA Corporation | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Coherus Oncology, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,614 in reported general payments places this provider in the 75th percentile of 68 medical oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 17 | $310,123 |
| EliquisApixaban | 31 | $17,953 |
| VenclextaVenetoclax | 14 | $15,464 |
| Posaconazole | 11 | $9,340 |
| Anastrozole | 38 | $962 |
| Dexamethasone | 16 | $414 |
| Ondansetron Hcl | 34 | $391 |
| Levofloxacin | 21 | $364 |
| Levothyroxine Sodium | 38 | $326 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 18 | $262 |
| Hydrocortisone | 13 | $234 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 29 | $206 |
| Ondansetron OdtOndansetron | 18 | $163 |
| Acyclovir | 18 | $162 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 15 | $148 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $64 | $310,12317 claims |
| PfizerEliquis | $226 | $17,95331 claims |
| AbbVieVenclexta | $26 | $15,46414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 68 medical oncology providers in Georgia.
Other medical oncology in Cumming
- Samir KhleifAugusta$337K
- Nabil SabaAtlanta$225K
- Sreekanth ReddyVidalia$116K
- Hagop YoussoufianDecatur$78K
- Suresh RamalingamAtlanta$75K
- Jonathan KaufmanAtlanta$73K
- Ragini KudchadkarAtlanta$69K
- Nisha JosephAtlanta$50K
- Eyal MeiriAtlanta$39K
- Bradley SumrallMacon$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.